Iterion Therapeutics – Tegavivint Phase 2 Clinical Trial
Dr. Rahul Aras, CEO of Iterion Therapeutics, a clinical stage biotechnology company developing novel cancer therapeutics discusses the company’s lead product, Tegavivint, a unique nuclear β-catenin inhibitor, which is currently advancing to a Phase 2 clinical trial in patients with progressive desmoid tumors. The company will also pursue additional clinical programs in acute myeloid leukemia (AML), non-small cell lung cancer (NSCLC), and pediatric cancers this year and in 2021.
Frequently Asked Questions
What is the main topic discussed in this episode of Health Professional Radio?
This episode covers important developments in healthcare, including updates on Cancer. Health Professional Radio brings you expert insights and analysis on the latest medical news affecting healthcare professionals and patients alike.
How can healthcare professionals benefit from this information?
Healthcare professionals can stay informed about the latest developments in Cancer and related fields, enabling them to provide better patient care. Staying current with medical news helps clinicians make evidence-based decisions in their practice.
Where can I find more information about Cancer?
For more detailed information, listen to the full episode on Health Professional Radio and visit hpr.fm for additional resources. You can also subscribe to our podcast for regular updates on healthcare news and expert interviews.
Dr. Aras joined Iterion as President and CEO in June 2018, bringing more than 15 years of experience in the biotechnology industry, including all aspects of raising funding, product development, business development and executive management. Prior to Iterion, he served as founding President & CEO of Juventas Therapeutics, where he successfully advanced their gene therapy platform from concept into mid-stage clinical trials and a partnership with a leading global pharmaceutical company. In addition, he has worked with several start-up biotechnology companies to accelerate growth through product proof of concept and value creation. He has held research positions at Vanderbilt University Medical Center and Massachusetts General Hospital and has published articles in several leading scientific journals. He received a B.S. from Tufts University and a Ph.D. in biomedical research from New York University.
Medical Disclaimer
The information provided on this website is for general informational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for medical advice, diagnosis, or treatment. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
